Among 3,727 consecutive patients with HF and LVEF of 50% or more, 8.3% had a clinician-assigned diagnosis of HFpEF, despite AI analysis demonstrating that as many as 75.4% met ESC diagnostic ...

In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac ...

Despite these clear criteria, diagnosis remains a challenge and is often made after excluding noncardiac causes. HFpEF affects an elderly patient population burdened by multiple comorbid conditions.

Although the features of HF as a clinical syndrome have been long recognized, the diagnostic criteria continue to evolve, ... This coupled with longstanding definitions of cardiac safety associated ...

Those who met the entry criteria were randomized to treatment with dapagliflozin 10 mg once daily or placebo for 24 weeks. ... “Remarkably, one-third of patients treated with dapagliflozin no longer ...

Until very recently, patients who were being considered for inclusion in HFpEF trials were not routinely screened for cardiac amyloidosis, for a simple reason: definitive diagnosis required ...

Ultromics, a pioneer in AI-driven cardiology solutions, has unveiled the latest enhancement to EchoGo® Heart Failure: the introduction of a first-of-its-kind AI-powered probability scoring system ...

In a world-first randomized study, catheter ablation has been shown to reverse heart failure with preserved ejection fraction (HFpEF) in patients with both HFpEF and atrial fibrillation (AF).

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients with obesity and HFpEF, ... According to the CDC, 40.3% of US adults meet criteria for obesity, ...